Galatea Bio and Fabric Genomics, a GeneDx (WGS) company, announced a strategic collaboration to enhance genetic testing by incorporating rare pathogenic variant analysis and polygenic risk scoring to assess genetic susceptibility to common diseases. The initial offering will include an inherited cardiovascular gene panel with PRS for cardiovascular traits, followed by hereditary cancer panels with PRS. The collaboration integrates Fabric Genomics’ platform with Galatea Bio’s StrataRisk PRS algorithms, utilizing Broad Clinical Lab’s Blended Genome – Exome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.